Concert begins Ph IIa of CTP-543 in alopecia areata

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) began a Phase IIa trial of CTP-543 to treat moderate to severe alopecia areata. The double-blind, U.S. trial will evaluate hair loss as measured by the Severity of Alopecia Tool (SALT) at week 24 in about 100 patients receiving 4, 8, 12 or 16 mg oral CTP-543 or placebo twice daily for 24 weeks. All patients will then receive CTP-543 for an additional 28 weeks. The trial will also evaluate safety...